MA52483A - Dérivés de gip et leurs utilisations - Google Patents

Dérivés de gip et leurs utilisations

Info

Publication number
MA52483A
MA52483A MA052483A MA52483A MA52483A MA 52483 A MA52483 A MA 52483A MA 052483 A MA052483 A MA 052483A MA 52483 A MA52483 A MA 52483A MA 52483 A MA52483 A MA 52483A
Authority
MA
Morocco
Prior art keywords
gip derivatives
gip
derivatives
Prior art date
Application number
MA052483A
Other languages
English (en)
Inventor
Nicholas Raymond Cox
Richard Dimarchi
Brian Finan
Wouter Frederik Johan Hogendorf
Patrick J Knerr
Jesper F Lau
Fa Liu
Steffen Reedtz-Runge
Henning Thøgersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA52483A publication Critical patent/MA52483A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA052483A 2018-05-04 2019-05-03 Dérivés de gip et leurs utilisations MA52483A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862666916P 2018-05-04 2018-05-04
EP18172827 2018-05-17

Publications (1)

Publication Number Publication Date
MA52483A true MA52483A (fr) 2021-03-10

Family

ID=66440040

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052483A MA52483A (fr) 2018-05-04 2019-05-03 Dérivés de gip et leurs utilisations

Country Status (20)

Country Link
US (3) US11633459B2 (fr)
EP (1) EP3788063B1 (fr)
JP (2) JP6818940B2 (fr)
KR (1) KR102379958B1 (fr)
CN (1) CN112074531A (fr)
AU (1) AU2019263674B2 (fr)
BR (1) BR112020022027A2 (fr)
CA (1) CA3097939A1 (fr)
CL (1) CL2020002796A1 (fr)
CO (1) CO2020014180A2 (fr)
ES (1) ES2961384T3 (fr)
IL (1) IL278171A (fr)
MA (1) MA52483A (fr)
MX (1) MX2020011427A (fr)
PE (1) PE20210473A1 (fr)
PH (1) PH12020551742A1 (fr)
RU (1) RU2020136305A (fr)
SG (1) SG11202010297UA (fr)
TW (1) TWI707865B (fr)
WO (1) WO2019211451A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7076432B2 (ja) 2016-09-09 2022-05-27 インサイト・コーポレイション Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
PE20210397A1 (es) 2018-02-20 2021-03-02 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer
JP6818940B2 (ja) * 2018-05-04 2021-01-27 ノヴォ ノルディスク アー／エス Ｇｉｐ誘導体およびその使用
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP4010338A1 (fr) 2019-08-06 2022-06-15 Incyte Corporation Formes solides d'un inhibiteur d'hpk 1
KR20220145888A (ko) 2020-03-06 2022-10-31 사노피 선택적 gip 수용체 작용제로서의 펩티드
CN115348876A (zh) 2020-03-31 2022-11-15 安塔罗斯医疗公司 用于成像和治疗目的的包含螯合部分的选择性gip受体激动剂
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
MX2023000303A (es) 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
JP2023551122A (ja) * 2020-11-09 2023-12-07 エンバーク バイオテック エーピーエス 化合物およびタキキニン受容体介在性障害の治療におけるその使用
BR112023025201A2 (pt) 2021-06-23 2024-02-27 Peptron Inc Composição de formulação de liberação sustentada compreendendo semaglutida, método para a produção de uma composição de formulação de liberação sustentada e uso da dita composição para tratar diabetes, obesidade, esteato-hepatite não alcoólica ou doença cerebral degenerativa
CA3230915A1 (fr) 2021-09-06 2023-03-09 Thomas Boehme Nouveaux peptides utilises en tant qu'agonistes puissants et selectifs du recepteur de gip
WO2023118263A1 (fr) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonistes pour le traitement d'un trouble de l'alimentation
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023151594A1 (fr) * 2022-02-11 2023-08-17 Hangzhou Sciwind Biosciences Co., Ltd. Composition comprenant des agonistes du récepteur gip et des agonistes du récepteur glp-1 et son utilisation
KR20240095076A (ko) 2022-12-16 2024-06-25 주식회사 펩트론 Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도
CN118255864A (zh) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 Gip受体激动剂及其用途
GB202302686D0 (en) * 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2300035B1 (fr) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l obésité
EP2987805A3 (fr) 2008-08-07 2016-04-13 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dépendant
PL2320923T3 (pl) 2008-08-07 2015-06-30 Ipsen Pharma Sas Skrócone analogi peptydu insulinotropowego zależnego od glukozy
MX339137B (es) * 2008-08-07 2016-05-13 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal.
US9072703B2 (en) 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
CN104311657B (zh) 2009-12-16 2020-12-08 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
EP2528618A4 (fr) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
EP2569000B1 (fr) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
WO2012036962A2 (fr) 2010-09-13 2012-03-22 Amylin Pharmaceuticals, Inc. Amidation c-terminale de polypeptides
US9023986B2 (en) * 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
EP2654774A4 (fr) 2010-12-22 2015-07-01 Marcadia Biotech Inc Méthodes de traitement des affections métaboliques et de l'obésité faisant appel à des peptides associés au glucagon, actifs sur les récepteurs gip et glp-1
EP2718317B1 (fr) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation
US20130090285A1 (en) 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
CA2877127A1 (fr) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogues du glucagon presentant une activite sur le recepteur du gip
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
ES2900744T3 (es) 2013-05-28 2022-03-18 Takeda Pharmaceuticals Co Compuesto de péptidos
EP3033112B1 (fr) 2013-08-15 2020-10-07 Novo Nordisk A/S Dérivés glp-1 et leurs utilisations
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CN106536547A (zh) * 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
EP3189072B1 (fr) 2014-09-05 2018-07-18 University of Copenhagen Peptides analogues du gip
WO2016066744A2 (fr) 2014-10-29 2016-05-06 Zealand Pharma A/S Composés agonistes de gip et procédés associés
ES2739289T3 (es) * 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016138335A1 (fr) 2015-02-27 2016-09-01 Lycera Corporation Thiadiazolamines indazolyle et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de maladies
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US20190175744A1 (en) 2016-03-18 2019-06-13 Merck Sharp & Dohme Corp. Insulin-incretin conjugates
WO2017210168A1 (fr) 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Agonistes hydrosolubles et chimiquement stables du depsi-glucagon
JP2020521784A (ja) * 2017-05-31 2020-07-27 ユニバーシティ オブ コペンハーゲン 長時間作用性ｇｉｐペプチド類似体
JP6818940B2 (ja) * 2018-05-04 2021-01-27 ノヴォ ノルディスク アー／エス Ｇｉｐ誘導体およびその使用

Also Published As

Publication number Publication date
IL278171A (en) 2020-11-30
TWI707865B (zh) 2020-10-21
WO2019211451A1 (fr) 2019-11-07
AU2019263674A1 (en) 2020-11-26
US10604555B2 (en) 2020-03-31
JP2020125311A (ja) 2020-08-20
US20240190938A1 (en) 2024-06-13
CO2020014180A2 (es) 2021-01-29
PE20210473A1 (es) 2021-03-08
CL2020002796A1 (es) 2021-02-19
MX2020011427A (es) 2020-12-07
TW202003550A (zh) 2020-01-16
BR112020022027A2 (pt) 2021-02-02
US20190367578A1 (en) 2019-12-05
AU2019263674B2 (en) 2023-03-02
US11633459B2 (en) 2023-04-25
CA3097939A1 (fr) 2019-11-07
RU2020136305A (ru) 2022-05-05
JP6818940B2 (ja) 2021-01-27
KR20210005700A (ko) 2021-01-14
US20220000982A1 (en) 2022-01-06
EP3788063B1 (fr) 2023-08-09
ES2961384T3 (es) 2024-03-11
EP3788063A1 (fr) 2021-03-10
EP3788063C0 (fr) 2023-08-09
JP2020528925A (ja) 2020-10-01
SG11202010297UA (en) 2020-11-27
KR102379958B1 (ko) 2022-04-01
PH12020551742A1 (en) 2021-06-28
CN112074531A (zh) 2020-12-11

Similar Documents

Publication Publication Date Title
MA52483A (fr) Dérivés de gip et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
MA55565A (fr) Agents de dégradation de stat et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA41598A (fr) Composés thérapeutiques de pyridazine et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA43205A (fr) Composés pyy sélectifs et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA50173A (fr) Composés activateurs de bisamide sarcomère et leurs utilisations
MA50413A (fr) Dérivés de benzimidazole et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA52411A (fr) Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales
MA43567A (fr) Anticorps pacap et leurs utilisations
MA52365A (fr) Composés et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA55385A (fr) Composés et leurs utilisations
MA52092A (fr) Composés et leurs utilisations